Danaher Corp.

Danaher designs, manufactures and markets medical, industrial and commercial products and services. The company's segments include: Life Sciences, which provides research tools to study genes, proteins, metabolites and cells, in order to understand the causes of disease, identify therapies and test drugs and vaccines; Diagnostics, which provides analytical instruments, reagents, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions; and Environmental and Applied Solutions, which provides products and services to protect resources and global food and water supplies.
  • TickerDHR
  • ISINUS2358511028
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States

Danaher Corp: 1 director

A director at Danaher Corp sold 6,006 shares at 254.750USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Danaher Corporation - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Danaher Corporation: Update to credit analysis

Our credit view of Danaher reflects its good scale and strong business diversity, tempered by aggressive financial policies pertaining to large acquisitions.

Danaher Corporation - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

An unfavourable environment weighs on DANAHER, which sees a downgrade to Neutral

The independent financial analyst theScreener just requalified the general evaluation of DANAHER (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as defensive. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Neutral. As of the analysis date March 5, 2021, the closing price was USD 218.35 and its target price was estimated at USD 197.01.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Market In “Wait-And-See” Phase We started to see waning upside momentum in the S&P 500 last week with the rising wedge breakdown and 2760 support level violation on Tuesday. Despite this, there was no downside follow through the following day as investors digested a new $484B fiscal relief package. This led to the S&P 500 finding support at 2725-2735 which leads us to where we are now -- testing recent highs. We see waning upside momentum and several aspects continue to suggest the S&P 500 remains vulnerable to a pullback, but the market is simply not breaking down. We believe some near-t...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Danaher Corp: 1 director

A director at Danaher Corp sold 6,006 shares at 254.750USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Valens Research

DHR - Embedded Expectations Analysis - 2021 03 02

Danaher Corporation (DHR:USA) currently trades at a historical high relative to UAFRS-based (Uniform) earnings, with a 31.4x Uniform P/E. At these levels, the market is pricing in bullish expectations for the firm, but management may be concerned about their vaccine and therapeutic projects, Cytiva and Pall Biotech margin growth, and core revenue growth across segments Specifically, management may lack confidence in their ability to sustain margin performance and shipment growth for Cepheid, expand margins for Cytiva and Pall Biotech, and maintain order growth for Cytiva. Furthermore, managem...

Valens Research

Valens Equity Insights and Inflections - 2020 12 15

The market is much more pessimistic about COF than any of the company's peers currently. The market looks at a lender to high-risk sub-prime borrowers in the midst of the pandemic and is worried Capital One's equity buffer is going to be severely pressured. Investors appear to forget how well Capital One fared the last time sub-prime borrowers got in trouble, when it was one of the best performers, and took significant share coming out of the Great Recession. While the market is pricing Capital One like its Uniform ROE will only ever reach half of what 2015-2017 trough levels were in the futur...

Valens Research

DHR - Embedded Expectations Analysis - 2020 12 14

Danaher Corporation (DHR:USA) currently trades at a historical high relative to UAFRS-based (Uniform) earnings, with a 34.7x Uniform P/E. At these levels, the market is pricing in bullish expectations for the firm, but management may be concerned about free cash flows, consumables & services performance, and investments Specifically, management may be concerned about their free cash flow generation, the effects of GeneXpert in different care settings, and the combinations of their investments in innovation, workforce, and a strong balance sheet. Moreover, they may lack confidence in their abi...

MarketLine Department

Ingersoll-Rand plc - Strategy, SWOT and Corporate Finance Report

Summary Ingersoll-Rand plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Ingersoll-Rand plc (Ingersoll or 'the company') is a designer, manufacturer and marketer of industrial and commercial products. The company's product portfolio includes air exchangers, air handlers, airside and terminal devices, aftermarket and OEM parts and supplies, auxiliary idle reduc...

MarketLine Department

Becton, Dickinson and Co - Strategy, SWOT and Corporate Finance Report

Summary Becton, Dickinson and Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Becton, Dickinson and Company (BD) is a global medical technology company. It is engaged in the development, manufacturing and sale of medical devices, laboratory equipment and diagnostic products. The company's major products include syringes and pen needles; intravenous catheters;...

Danaher Corporation - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Danaher Corporation: Update to credit analysis

Our credit view of Danaher reflects its good scale and strong business diversity, tempered by aggressive financial policies pertaining to large acquisitions.

Danaher Corporation - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Danaher Corporation - October 2020 (LTM): Peer Snapshot

Peer Snapshot:  Danaher Corporation - October 2020 (LTM) 26 November 2020 (in US millions) FYE Dec-18 FYE Dec-19 LTM Oct-20 FYE Dec-18 FYE Dec-19 LTM Sep-20 FYE Dec-18 FYE Dec-19 LTM Sep-20

Danaher Corporation - July 2020 (LTM): Peer Snapshot

Peer Snapshot:  Danaher Corporation - July 2020 (LTM) 31 August 2020 (in US millions) FYE Dec-18 FYE Dec-19 LTM Jul-20 FYE Dec-18 FYE Dec-19 LTM Jun-20 FYE Dec-18 FYE Dec-19 LTM Jun-20

An unfavourable environment weighs on DANAHER, which sees a downgrade to Neutral

The independent financial analyst theScreener just requalified the general evaluation of DANAHER (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as defensive. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Neutral. As of the analysis date March 5, 2021, the closing price was USD 218.35 and its target price was estimated at USD 197.01.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch